Chen Ching-En, Chou Ruey-Hsing, Guo Jiun-Yu, Lu Ya-Wen, Chang Chun-Chin, Wu Cheng-Hsueh, Huang Po-Hsun
Division of Plastic and Reconstructive Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
PLoS One. 2025 Aug 29;20(8):e0330668. doi: 10.1371/journal.pone.0330668. eCollection 2025.
Beyond the well-established classical renin-angiotensin system (RAS), emerging evidence highlights the critical role of the non-classical RAS, specifically the Angiotensin (1-7)/ACE2/Mas axis. As the key enzyme converting Angiotensin II into Angiotensin (1-7), angiotensin-converting enzyme 2 (ACE2) exerts cardioprotective and anti-inflammatory effects, showing potential therapeutic value in critical care. This study investigates the association between circulating ACE2 levels and clinical outcomes in sepsis, offering insights into its role and potential for predicting sepsis outcomes.
In this single-center study, we investigated associations between the circulating ACE2 concentration and outcomes in septic patients admitted to a medical intensive care unit (ICU) between 01/05/2018 and 31/01/2021. Sepsis was defined as infection accompanied by a ≥2-point Sequential Organ Failure Assessment (SOFA) score increase. Patients were categorized into low (<2.5 ng/mL) and high (≥2.5 ng/mL) ACE2 groups based on serum concentrations within 24 hours of ICU admission. Outcomes comprised acute kidney injury (AKI), ICU mortality, and 90-day mortality.
In total, 414 patients (mean age 68.5 years, 64.7% male) were included in the study. Elevated ACE2 levels correlated positively with SOFA score and total bilirubin and lactate concentrations, and negatively with the hemoglobin concentration. Relative to the low ACE2 group, the high ACE2 group was at increased risk of sepsis-associated AKI development within 48 hours after ICU admission (81.6% vs. 69.6%, p = 0.006), AKI requiring renal replacement therapy (21.3% vs. 11.1%, p = 0.007), ICU mortality (31.9% vs. 17.5%, p = 0.001), and 90-day mortality (51.7% vs. 39.6%, p = 0.018). Kaplan-Meier survival curves demonstrated significantly reduced survival in individuals with high ACE2 concentrations (p = 0.009). Univariate analysis revealed significant associations of high ACE2 concentrations with ICU mortality and AKI development within 48 hours after ICU admission. In a multivariate analysis adjusted for relevant variables, ACE2 elevation remained an independent predictor of ICU mortality (adjusted odds ratio 2.15, 95% confidence interval 1.04-4.41, p = 0.038).
Elevated circulating ACE2 concentrations comprised an independent predictor of ICU mortality, highlighting intricate RAS dynamics in critical illnesses. Low ACE2 concentrations were associated with greater survival, suggesting their potential as an early prognostic indicator.
除了已被充分证实的经典肾素 - 血管紧张素系统(RAS)外,新出现的证据突出了非经典RAS的关键作用,特别是血管紧张素(1 - 7)/ACE2/ Mas轴。作为将血管紧张素II转化为血管紧张素(1 - 7)的关键酶,血管紧张素转换酶2(ACE2)发挥心脏保护和抗炎作用,在重症监护中显示出潜在的治疗价值。本研究调查了脓毒症患者循环ACE2水平与临床结局之间的关联,以深入了解其在预测脓毒症结局中的作用和潜力。
在这项单中心研究中,我们调查了2018年5月1日至2021年1月31日期间入住内科重症监护病房(ICU)的脓毒症患者循环ACE2浓度与结局之间的关联。脓毒症定义为伴有序贯器官衰竭评估(SOFA)评分增加≥2分的感染。根据ICU入院后24小时内的血清浓度,将患者分为低(<2.5 ng/mL)和高(≥2.5 ng/mL)ACE2组。结局包括急性肾损伤(AKI)、ICU死亡率和90天死亡率。
本研究共纳入414例患者(平均年龄68.5岁,64.7%为男性)。ACE2水平升高与SOFA评分、总胆红素和乳酸浓度呈正相关,与血红蛋白浓度呈负相关。与低ACE2组相比,高ACE2组在ICU入院后48小时内发生脓毒症相关AKI的风险增加(81.6%对69.6%,p = 0.006),需要肾脏替代治疗的AKI(21.3%对11.1%,p = 0.007),ICU死亡率(31.9%对17.5%,p = 0.001)和90天死亡率(51.7%对39.6%,p = 0.018)。Kaplan - Meier生存曲线显示,ACE2浓度高的个体生存率显著降低(p = 0.009)。单因素分析显示,高ACE2浓度与ICU死亡率以及ICU入院后48小时内AKI的发生显著相关。在对相关变量进行调整的多因素分析中,ACE2升高仍然是ICU死亡率的独立预测因素(调整后的优势比为2.15,95%置信区间为1.04 - 4.41,p = 0.038)。
循环ACE2浓度升高是ICU死亡率的独立预测因素,突出了危重病中复杂的RAS动态变化。低ACE2浓度与更高的生存率相关,表明其作为早期预后指标的潜力。